Patchliner application note: (0.6 MB)
Cells were kindly provided by Axiogenesis.
Although mouse embryonic stem (ES) cell-derived cardiomyocytes, e.g. Cor.At® cells from Axiogenesis, can provide a useful model for drug discovery and safety testing as an alternative to acutely dissociated rat or mouse cardiomyocytes, human induced pluripotent (iPS) cell-derived cardiomyocytes have the potential to provide the ultimate model system for identifying potential antiarrythmic effects of drugs during routine safety screening. Axiogenesis has now launched the Cor.4U® human iPS cell-derived cardiomyocyte product line for use in testing the efficacy and safety of pharmaceutical therapies. The ability to characterize the ion channel profile of these cells and reliably record action potentials at a reasonable throughput is essential to fully realise the potential of this kind of product line. Building on the success of Cor. At® mouse embryonic stem (ES) cell-derived cardiomyocytes on the Patchliner, Cor.4U® human iPS cell-derived cardiomyocytes have now been characterized on the Patchliner in the voltage and current clamp modes. In this Application Note we present data using an 8-channel Patchliner characterizing Cor.4U® cells. In the voltage clamp mode, voltage-dependent Na+ (NaV), K+ (KV) and hERG (an inward current using a high K+-containing external solution) channel currents were recorded (Fig. 1). When the Ca2+ channel agonist BayK 8644 was used a voltage-gated Ca2+ (CaV) current could be recorded. As expected, action potentials could be elicited in the current clamp mode. The effect of the compounds TTX and BayK 8644 on the action potentials evoked in Cor.4U cells is also shown.